Neurocrine Biosciences, Inc. Stock News

Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.

SAN DIEGO , Dec. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints. The primary objective of the study was to assess improvement in chore...

Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs Transcript

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities Reviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027 Announced Expansion of CRF Platform as Foundation of New ...

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m.

Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone.

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration and robust clinical data across diverse patient populations and concludes t...